Q-omics provides the consensus-scored CDK18 profile across patient tissues and cancer cell-line models. CDK18 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, CDK18 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, CDK18 protein abundance shows 26,631 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight BLCA, KIRC, and GBM as cancer lineages where CDK18 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CDK18 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CDK18 survival associations across molecular data types. CDK18 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (2) and mass-spec protein abundance (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CDK18 RNA expression–survival associations across cancer types. High CDK18 expression shows unfavorable associations in KIRP, LAML and LIHC, but favorable associations in BLCA, DLBC and KIRC. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for CDK18 RNA expression.
This table summarizes CDK18 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 9. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for CDK18. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CDK18 shows lower tumor expression in KICH and higher tumor expression in KIRC, HNSC, COAD, BLCA and CHOL. The KIRC box plot shows higher CDK18 RNA expression in tumor versus normal tissue (log2 FC = +2.385, t-test p < 0.001).
This table shows molecular features associated with CDK18 in patient tissues and cancer cell lines. In patient samples, CDK18 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, CDK18 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Leukemia.
